Aldeyra Therapeutics
Jun 20, 2023
FDA Extended the Review Period for Momelotinib; FDA Approves Roche’s Columvi; Avita Medical Obtains FDA Approval of RECELL; FDA Approves Odevixibat for ALGS; TME Pharma Receives IND Approval for NOX-A12; Aldeyra’s Phase 3 INVIGORATE‑2 Trial of Reproxalap
GSK Announces Extension of FDA Review Period for Momelotinib After all, GSK will not hear from the FDA this month about its marketing application for momelotinib as a therapy for anemia in myelofibrosis patients. The pharmaceutical company announced that the US Food and Drug Administration has extended the drug'...
Read More...
Apr 18, 2023
RegeneRx’s Phase 3 Neurotrophic Keratitis Clinical Trial of RGN-259; Aldeyra’s Phase 3 INVIGORATE-2 Clinical Trial Update; FDA Orphan Drug Designation to Oncolyze’s OM-301 for Multiple Myeloma; Soligenix Provides Regulatory Update on HyBryte; FDA Fast Track Designation to SAB Biotherapeutics’s SAB-176 Influenza Immunotherapy; Aviceda IND Application for AVD-104
RegeneRx Biopharmaceuticals Enrolled First Patient in the Phase 3 Neurotrophic Keratitis Clinical Trial with RGN-259 in the US On April 12, 2023, RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or "Company") announced that the first patient of Phase 3 clinical trial (SEER-2) of RGN-259, a novel treat...
Read More...
Feb 14, 2023
Leo Pharma’s Hand Eczema Clinical Trial Updates; GSK’s PD-1 inhibitor Jemperli Approval; Roche Announces Phase III Result of Vabysmo; FDA Accepts NDA for Aldeyra’s reproxalap; RMAT and Fast Track Designations to IASO Bio’s CT103A; Orphan Drug Designation to Jubilant Therapeutics’s JBI-778
Leo Pharma Announces Positive Results of Phase III Hand Eczema Clinical Trial LEO Pharma A/S, a global leader in medical dermatology, announced that the DELTA 2 trial yielded positive results. DELTA 2 is the second of two pivotal phase III clinical trials involving delgocitinib cream, an investigational topical ...
Read More...
Jul 09, 2018
Allergic Conjunctivitis (AC) – Common disorder with increasing prevalence
Allergic Conjunctivitis (AC) is a common eye disorder characterized by the inflammation in the tissue that lines the inside of eyelid and outside of the eyeball called conjunctiva. It usually happens when a person’s eyes come into contact with an allergen, a substance that makes the body’s immune system to overreact...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
